deCODE genetics to Webcast Presentation at Piper Jaffray Europe Conference

REYKJAVIK, Iceland, June 19 /PRNewswire-FirstCall/ -- deCODE genetics
(Nasdaq: DCGN) today announced that it will host a live webcast of deCODE CEO
Kari Stefansson's presentation at the Piper Jaffray Europe Conference.
The presentation will be delivered on Wednesday, June 25, at 7am Eastern
Time/11am GMT/12 noon British Summer time, at the ANdAZ hotel in London. The
webcast can be accessed through the Investors page on deCODE's website,
www.decode.com, and those interested in listening should log on a few minutes
in advance in order to download any software or complete any sign-in that may
be required. The webcast will be archived for at least one week.
About deCODE
deCODE is a biopharmaceutical company applying its discoveries in human
genetics to the development of diagnostics and drugs for common diseases.
deCODE is a global leader in gene discovery - our population approach and
resources have enabled us to isolate key genes contributing to major public
health challenges from cardiovascular disease to cancer, genes that are
providing us with drug targets rooted in the basic biology of disease. Through
its CLIA-registered laboratory, deCODE is offering a growing range of
DNA-based tests for gauging risk and empowering prevention of common diseases,
including deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial
fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProCa(TM) for
prostate cancer; and deCODE Glaucoma(TM) for a major type of glaucoma. deCODE
is delivering on the promise of the new genetics.(SM) Visit us on the web at
www.decode.com; on our diagnostics website at www.decodediagnostics.com; and,
for our pioneering personal genome analysis service, at www.decodeme.com.
Any statements contained in this presentation that relate to future plans,
events or performance are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to a number of risks and uncertainties that could cause
actual results, and the timing of events, to differ materially from those
described in the forward-looking statements. These risks and uncertainties
include, among others, those relating to our ability to obtain financing and
to form collaborative relationships, uncertainty regarding potential future
deterioration in the market for auction rate securities which could result in
additional permanent impairment charges, our ability to develop and market
diagnostic products, the level of third party reimbursement for our products,
risks related to preclinical and clinical development of pharmaceutical
products, including the identification of compounds and the completion of
clinical trials, the effect of government regulation and the regulatory
approval processes, market acceptance, our ability to obtain and protect
intellectual property rights for our products, dependence on collaborative
relationships, the effect of competitive products, industry trends and other
risks identified in deCODE's filings with the Securities and Exchange
Commission, including, without limitation, the risk factors identified in our
most recent Annual Report on Form 10-K and any updates to those risk factors
filed from time to time in our Quarterly Reports on Form 10-Q or Current
Reports on Form 8-K. deCODE undertakes no obligation to update or alter these
forward-looking statements as a result of new information, future events or
otherwise.
Contacts:
Gisli Arnason Joy Bessenger
+354 570 1825 +1 212 481 3891
gisli.arnason@decode.is joy.bessenger@decode.is

SOURCE deCODE genetics

Gisli Arnason, +354 570 1825, gisli.arnason@decode.is, or Joy Bessenger,
+1-212-481-3891, joy.bessenger@decode.is, both of deCODE genetics